Follow Neurocrine Biosciences to never miss an important update.
Guggenheim kept its buy rating on the company and set a price target of $224. This is notably higher than the average analyst target of $203 and the current stock price of about $168. Several other firms also adjusted their targets this week following the company's recent quarterly results. While a price target is just an analyst's estimate of where the stock might trade in a year, it shows confidence in the company's ability to grow its new treatments for rare diseases. These new drugs are becoming a larger part of the business, helping it move away from relying solely on its flagship movement-disorder medicine.
Source: Guggenheim
After Neurocrine Biosciences reported its November results, we updated our fair value and moved our rating to Watch. We raised our expectations for revenue and cash flow to account for the faster rollout of the adrenal disorder treatment Crenessity. We added the company's new obesity drug pipeline and the recently acquired Vykat XR portfolio to what we track. We also started monitoring the share of revenue coming from new products to judge how well the business is diversifying beyond its primary blockbuster drug.
Neurocrine reported a standout quarter with revenue growing 41 percent to 1.12 billion dollars, well ahead of the 1.04 billion dollars analysts expected. Earnings per share reached $3.29, nearly double the $1.91 that was forecast. This jump was driven by record demand for Ingrezza, the company's treatment for involuntary movements, which crossed the 1 billion dollar quarterly sales mark for the first time.
Management also raised its full-year sales outlook for Ingrezza to about 2.9 billion dollars. This performance is a strong sign that the company is successfully funding its newer treatments, like the adrenal disorder drug Crinecerfont, using the cash generated by its first hit product. For a long-term owner, this quarter shows the business is scaling faster than expected and has the financial room to build a much broader portfolio of medicines.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
The company is expected to report revenue of about 1.04 billion dollars. The main thing to watch is the sales growth of Ingrezza, the treatment for involuntary movements that currently funds the rest of the business. We will also look for updates on the rollout of Crinecerfont, a new treatment for adrenal gland disorders. That launch is a key part of the plan to diversify the company's income so it doesn't rely so heavily on a single drug.
Neurocrine shared a new analysis of its main drug, Ingrezza, which treats tardive dyskinesia, a condition that causes involuntary body movements. The study established a specific 6-point score increase as the benchmark for a "meaningful" improvement in a patient's daily life. Patients in the trial actually reported an average gain of 13 points, more than double that bar. This matters because it gives doctors a clearer way to measure how much the drug is actually helping a patient's overall well-being beyond just reducing physical movements. For a company that relies on this single drug for most of its revenue, proving it has a deep, measurable impact on quality of life helps keep it as the preferred choice for doctors and insurers.
Source: PRNewsWire
Management has a history of setting conservative targets and then blowing past them, with the last six quarters showing a business that is consistently outrunning even the most optimistic forecasts.
| Expectation | |
|---|---|
| EPS | $2.07 |
| Revenue | $1.09B |
Follow Neurocrine Biosciences to get the latest and most important updates.
Follow NBIX